ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin);  ;  ; leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) - injection with diluent - 7.5 mg - active: leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin);  ;  ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin);  ;  ; leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) - injection with diluent - 30 mg - active: leuprorelin acetate 30mg (includes 35.8mg leuprorelin acetate to deliver 30mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 30mg (includes 37.2mg leuprorelin acetate to deliver 30mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin);  ;  ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

takeda uk limited - leuprorelin acetate - pdr+solv for susp for inj - 11.25 milligram - gonadotropin releasing hormone analogues

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

takeda uk limited - leuprorelin acetate - unknown - 30 milligram - gonadotropin releasing hormone analogues

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

takeda uk limited - leuprorelin acetate - pdr+solv for susp for inj - 3.75 milligram - gonadotropin releasing hormone analogues

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - leuprorelin acetate - powder and solvent for suspension for injection - 3.75 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones analogues - it is indicated for palliative treatment of locally advanced or metastatic prostate cancer

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

mercury pharmaceuticals ltd - leuprorelin acetate - powder and solvent for suspension for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin - endocrine therapy. hormones and related agents. gonadotropin-releasing hormones analogues - it t is indicated for palliative treatment of hormone dependent advanced prostate cancer

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

takeda uk ltd - leuprorelin acetate - powder and solvent for suspension for injection - 3.75mg